Analyzing Liminatus Pharma (LIMN) and Its Competitors

Liminatus Pharma (NASDAQ:LIMN) is one of 862 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Liminatus Pharma to similar businesses based on the strength of its institutional ownership, analyst recommendations, risk, profitability, earnings, dividends and valuation.

Earnings & Valuation

This table compares Liminatus Pharma and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Liminatus Pharma	N/A	-$10.21 million	-9.95
Liminatus Pharma Competitors	$725.66 million	$15.88 million	-11.83

Liminatus Pharma’s competitors have higher revenue and earnings than Liminatus Pharma. Liminatus Pharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Liminatus Pharma has a beta of 5.34, meaning that its stock price is 434% more volatile than the S&P 500. Comparatively, Liminatus Pharma’s competitors have a beta of 1.23, meaning that their average stock price is 23% more volatile than the S&P 500.

Institutional & Insider Ownership

48.0% of shares of all “Biotechnology” companies are held by institutional investors. 19.4% of Liminatus Pharma shares are held by company insiders. Comparatively, 12.9% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Liminatus Pharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-256.58%
Liminatus Pharma Competitors	-9,375.31%	-127.87%	-33.50%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Liminatus Pharma and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1	0	0	0	1.00
Liminatus Pharma Competitors	9317	14842	44399	1481	2.54

As a group, “Biotechnology” companies have a potential upside of 56.03%. Given Liminatus Pharma’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Liminatus Pharma has less favorable growth aspects than its competitors.

Summary

Liminatus Pharma competitors beat Liminatus Pharma on 8 of the 13 factors compared.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.